FUSION ANTIBODIES PLC (FAB) — Company update

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the FUSION ANTIBODIES PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and publish responses, which is appropriate to do so. Before we begin, I would like to submit the following poll. I would now like to hand you over to CEO, Adrian Kincaid. Good morning to you. Thank you very much, Alex. Thank you very much, everyone, for attending. Stephen and I will do our best to take you through the presentation. It's probably worth pointing out for anyone who doesn't already know that the financials that's for the the year ending 03/31/2025 are going through the audit process as you would expect. So we can't comment to him in any more depth than we've already said in the trading update on the financials themselves. So Steven will have an easier time of it today. But the company is going through a really exciting time, so we certainly wanted to expand on the points that we've put out in the trading update and explain more about what that means for the business going forward. So much of the presentation today will be focused on on that side of things. So without any further ado, I will move us forward. There is, of course, the natural the usual disclaimer that I will take it that everybody has read. And for anybody who's not familiar with fusion antibodies, essentially, are a contract research organization or we sometimes prefer to call it collaborative resear...